Aged tendency of population stimulates the development of POCT industry
With the progress of medical technology and the development of social economics, the average life expectancy of human beings has been significantly improved. However, this kind of human social progress has brought a huge challenge -- population aging. At present, the proportion of the elderly population in the world is increasing rapidly. According to the World Social Report 2023 released by the United Nations on January 12th, the global population aged 65 and above is 761 million in 2021, and this number will increase to 1.6 billion by 2050. The population aged 80 and above is growing faster.
The emergence of aging population will have a great impact on society, one of the most obvious effects is the sharp increase in medical needs of the elderly. As long as getting old age, people easily get the chronic diseases, such as cardiovascular diseases, diabetes, Alzheimer's disease and osteoporosis, and these stimulate the medical needs of aged populations. The traditional medical system is difficult to satisfied the rapid growth of the elderly population and the personalized medical needs, which promoted the development of POCT technology.
Because the aged populations are susceptible to many diseases, the speed and accuracy of diagnosis and treatment play a vital role in their health and life safety. POCT technology is suitable for rapid diagnosis and treatment in hospital, clinics and rescues etc. because of its advantages of rapidity, accuracy, simplicity and reliability, which can effectively improve the medical service level, health protection and quality of life for the aged populations .
In addition, with the continuous progress of science and technology, POCT technology is constantly upgrading, such as prenatal screening and early diagnosis of lung cancer, breast cancer, hepatitis and other diseases, which makes the elderly get better attention and treatment in medical care. Therefore, with the ongoing of population aging, POCT technology will continue to usher in greater development opportunities in the future.
WIZ, as a POCT enterprise engaged in the research, development, production and sales of rapid diagnostic reagents and instruments, has produced more than 80 certified reagents through ten years development, covering digestive tract diseases, infectious diseases, tumor markers, inflammatory markers, thyroid function, sex hormones, drugs abuse and other products, which can meet the detection needs of different people. The quality and safety of our products have been recognized by many customers and our products have been exported to Germany, Italy, Spain, Finland, the Netherlands, Indonesia, Malaysia, Peru and other countries. WIZ will continually devote itself to global health development from now on.
